CN111588715A - 杨梅素抑制新型冠状病毒的药物应用 - Google Patents

杨梅素抑制新型冠状病毒的药物应用 Download PDF

Info

Publication number
CN111588715A
CN111588715A CN202010493810.0A CN202010493810A CN111588715A CN 111588715 A CN111588715 A CN 111588715A CN 202010493810 A CN202010493810 A CN 202010493810A CN 111588715 A CN111588715 A CN 111588715A
Authority
CN
China
Prior art keywords
myricetin
ncov
novel coronavirus
inhibiting
application
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010493810.0A
Other languages
English (en)
Inventor
宋昆元
陈伟伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Aiqi Pharmaceutical Technology Co Ltd
Original Assignee
Shanghai Aiqi Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Aiqi Pharmaceutical Technology Co Ltd filed Critical Shanghai Aiqi Pharmaceutical Technology Co Ltd
Priority to CN202010493810.0A priority Critical patent/CN111588715A/zh
Priority to PCT/CN2020/096824 priority patent/WO2021243756A1/zh
Priority to US17/287,417 priority patent/US20220040142A1/en
Publication of CN111588715A publication Critical patent/CN111588715A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明提供了一种杨梅素抑制新型冠状病毒的药物应用，研究证明杨梅素能结合2019‑nCoV‑Mpro蛋白酶，其针对新型冠状病毒(2019‑nCoV)的靶点Mpro的IC50值为0.582±0.0912μM，具有显著效果，能够抑制2019‑nCoV病毒。

Description

杨梅素抑制新型冠状病毒的药物应用
技术领域
本发明属于医药技术领域，具体涉及一种杨梅素抑制新型冠状病毒的药物应用。
背景技术
新冠肺炎自2020年世界范围内爆发，并且可能和人类长期共存，目前无批准的特效药可用。
3-胰凝乳蛋白酶样蛋白酶(3-chymotrypsin-like protease)，即主要蛋白酶(Mpro，也称为3CLpro)，由ORF1编码(定位于nsp5)，位于复制酶基因中心区域，是新型冠状病毒RNA复制时的一个关键蛋白质。其作用机制为：新冠病毒入侵细胞后，会利用宿主细胞合成自身复制必需的两条超长复制酶多肽(pp1a和pp1ab)。复制酶多肽需进一步被剪切成多个蛋白(如RdRp、helicase等)，进一步组装成用于病毒启动自身遗传物质复制所需的复制转录机器。Mpro在复制酶多肽上存在至少11个切割位点，只有当复制酶多肽上这些位点被正常切割后，组装成复制转录机器，启动病毒复制。鉴于Mpro蛋白酶在病毒复制过程中至关重要，且人体中并无类似的蛋白质，因此主蛋白酶Mpro成为一个抗新冠病毒的潜在关键药靶。
发明内容
本发明目的是提供一种能够抑制新型冠状病毒(2019-nCoV)的药物：杨梅素。
本发明提供了一种杨梅素在抑制新型冠状病毒(2019-nCoV)方面的应用。
进一步，在本发明提供的应用中，还可以具有这样的特征：杨梅素能结合2019-nCoV-Mpro蛋白酶，从而抑制2019-nCoV病毒。
附图说明
图1是本发明的实验例中杨梅素对新型冠状病毒(2019-nCoV)的靶点Mpro的的IC50值的计算图。
本发明提供了如下优点：
本发明所涉及的杨梅素能结合2019-nCoV-Mpro蛋白酶，其针对新型冠状病毒(2019-nCoV)的靶点Mpro的IC50值为0.582±0.0912μM，具有显著效果，能够抑制2019-nCoV病毒。
具体实施方式
为了使本发明实现的技术手段、创作特征、达成目的与功效易于明白了解，以下结合实施例对本发明的杨梅素在抑制新型冠状病毒方面的药物应用作具体阐述。
杨梅素：英文名称：Myricetin；中文化学名：3,5,7-三羟基-2-(3,4,5-三羟基苯基)-4H-1-苯并呋喃-4-酮；英文化学名：3,3',4',5,5',7-Hexahydroxyflavone；CAS号：529-44-2；分子式：C15H10O8；分子量：318.24；化学结构：
Figure BDA0002522040570000021
杨梅素具有抑制新型冠状病毒(2019-nCoV)的效果。
<实验实施例>
本实施例为靶向2019-nCoV病毒Mpro蛋白酶活性抑制检测。
利用荧光共振能量转移方法评价测定杨梅素对2019-nCoV-Mpro蛋白酶的抑制活性。
检测方法：整个酶促反应体系的体积为120μL，蛋白酶的终浓度为30nM，底物终浓度为20μM。反应体系的缓冲液包括50mM Tris pH7.3、1mM EDTA。在96孔板中加入2019-nCoV-Mpro蛋白酶和不同浓度的杨梅素，30℃孵育10min，加入底物并迅速放入酶标仪中读数。激发光和发射光分别为340nm和405nm。测试时间为10min，每隔30s读一次荧光值。最终结果取前2min的读值拟合反应速率，并与对照组(DMSO)比较，计算抑制率。以Graghpad-prism5.0作图，如图1，计算杨梅素对应时间点IC50值。
检测结果如表1所示：
表1.杨梅素靶向2019-nCoV-Mpro蛋白酶活性测试结果
样品 IC50(μg/ml) IC50(μM)
杨梅素 0.185±0.029μg/ml 0.582±0.0912μM
从表1中可以看出杨梅素针对新型冠状病毒(2019-nCoV)的靶点Mpro的IC50值为0.582±0.0912μM，具有显著效果。
本发明所涉及的杨梅素抑制新型冠状病毒的药物应用并不限于具体实施例的范围。以上内容仅为本发明的基本说明，而依据本发明的技术方案所作的任何等效变换，均应属于本发明的保护范围。

Claims (2)

1.杨梅素在抑制新型冠状病毒(2019-nCoV)方面的应用。
2.根据权利要求1所述的应用，其特征在于：杨梅素能结合2019-nCoV-Mpro蛋白酶，从而抑制2019-nCoV病毒。
CN202010493810.0A 2020-06-03 2020-06-03 杨梅素抑制新型冠状病毒的药物应用 Pending CN111588715A (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202010493810.0A CN111588715A (zh) 2020-06-03 2020-06-03 杨梅素抑制新型冠状病毒的药物应用
PCT/CN2020/096824 WO2021243756A1 (zh) 2020-06-03 2020-06-18 杨梅素抑制新型冠状病毒的药物应用
US17/287,417 US20220040142A1 (en) 2020-06-03 2020-06-18 Pharmaceutical application for the inhibition of novel coronaviruses by myricetin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010493810.0A CN111588715A (zh) 2020-06-03 2020-06-03 杨梅素抑制新型冠状病毒的药物应用

Publications (1)

Publication Number Publication Date
CN111588715A true CN111588715A (zh) 2020-08-28

Family

ID=72186017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010493810.0A Pending CN111588715A (zh) 2020-06-03 2020-06-03 杨梅素抑制新型冠状病毒的药物应用

Country Status (3)

Country Link
US (1) US20220040142A1 (zh)
CN (1) CN111588715A (zh)
WO (1) WO2021243756A1 (zh)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111450088A (zh) * 2020-04-30 2020-07-28 上海爱启医药技术有限公司 二杨梅素基二硒醚的药物应用
CN112168899A (zh) * 2020-09-30 2021-01-05 上海中医药大学 抑制冠状病毒3cl蛋白水解酶的藤茶提取物及其用途
CN112546038A (zh) * 2020-11-19 2021-03-26 澳门科技大学 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
EP4011367A1 (en) * 2020-12-09 2022-06-15 Dompe' Farmaceutici S.P.A. Compounds for use in the treatment of covid-19
CN114983993A (zh) * 2021-03-02 2022-09-02 中国科学院上海药物研究所 杨梅素和二氢杨梅素磷酸酯类化合物在防治新冠肺炎药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101701245A (zh) * 2009-10-21 2010-05-05 中国科学院生物物理研究所 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法
CN107898778A (zh) * 2017-11-16 2018-04-13 南方医科大学 杨梅素在制备抗流感病毒药物中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605335A (zh) * 2003-05-30 2005-04-13 任启生 含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物
CN1644199A (zh) * 2003-05-30 2005-07-27 任启生 蛇葡萄素在制备广谱抗病毒药物中的用途
KR20130031551A (ko) * 2011-09-21 2013-03-29 동국대학교 산학협력단 사스 코로나바이러스의 활성을 억제하는 플라보노이드, 약학적으로 허용가능한 유도체 및 염, 이를 함유하는 사스 치료 또는 예방용 조성물 및 건강기능식품
US20140194500A1 (en) * 2013-01-08 2014-07-10 Kookmin University Industry Academic Cooperation Foundation Methods For Treating of SARS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101701245A (zh) * 2009-10-21 2010-05-05 中国科学院生物物理研究所 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法
CN107898778A (zh) * 2017-11-16 2018-04-13 南方医科大学 杨梅素在制备抗流感病毒药物中的应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LIU H ET AL: "Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro", 《BIORXIV》 *
MANI JS ET AL: "Natural product-derived phytochemicals as potential agents against", 《VIRUS RESEARCH》 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111450088A (zh) * 2020-04-30 2020-07-28 上海爱启医药技术有限公司 二杨梅素基二硒醚的药物应用
CN112168899A (zh) * 2020-09-30 2021-01-05 上海中医药大学 抑制冠状病毒3cl蛋白水解酶的藤茶提取物及其用途
CN112168899B (zh) * 2020-09-30 2022-07-01 上海中医药大学 抑制冠状病毒3cl蛋白水解酶的藤茶提取物及其用途
CN112546038A (zh) * 2020-11-19 2021-03-26 澳门科技大学 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
EP4011367A1 (en) * 2020-12-09 2022-06-15 Dompe' Farmaceutici S.P.A. Compounds for use in the treatment of covid-19
WO2022122968A1 (en) * 2020-12-09 2022-06-16 Dompe' Farmaceutici Spa Compounds for use in the treatment of covid-19
CN114983993A (zh) * 2021-03-02 2022-09-02 中国科学院上海药物研究所 杨梅素和二氢杨梅素磷酸酯类化合物在防治新冠肺炎药物中的应用
CN114983993B (zh) * 2021-03-02 2023-11-17 中国科学院上海药物研究所 杨梅素和二氢杨梅素磷酸酯类化合物在防治新冠肺炎药物中的应用

Also Published As

Publication number Publication date
US20220040142A1 (en) 2022-02-10
WO2021243756A1 (zh) 2021-12-09

Similar Documents

Publication Publication Date Title
CN111588715A (zh) 杨梅素抑制新型冠状病毒的药物应用
Li et al. Ribonuclease L mediates the cell-lethal phenotype of double-stranded RNA editing enzyme ADAR1 deficiency in a human cell line
Matsumura et al. Overexpression of Bax inhibitor suppresses the fungal elicitor‐induced cell death in rice (Oryza sativa L.) cells
Chenon et al. A viral deubiquitylating enzyme targets viral RNA‐dependent RNA polymerase and affects viral infectivity
Kim et al. Formation of apoptosome is initiated by cytochrome c-induced dATP hydrolysis and subsequent nucleotide exchange on Apaf-1
Lee et al. Aminoacyl-tRNA synthetases, therapeutic targets for infectious diseases
Lilley et al. DNA repair proteins affect the lifecycle of herpes simplex virus 1
Mukherjee et al. Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection
Tokarz et al. SENP proteases as potential targets for cancer therapy
Wang et al. The Marsupenaeus japonicus voltage-dependent anion channel (MjVDAC) protein is involved in white spot syndrome virus (WSSV) pathogenesis
Calderon et al. A human cellular noncoding RNA activates the antiviral protein 2′–5′-oligoadenylate synthetase 1
Krishnan et al. Polysome profiling reveals broad translatome remodeling during endoplasmic reticulum (ER) stress in the pathogenic fungus Aspergillus fumigatus
CN111450088B (zh) 二杨梅素基二硒醚的药物应用
Han et al. Quantitative proteomic analysis of duck ovarian follicles infected with duck Tembusu virus by label-free LC-MS
Karakasiliotis et al. Cellular senescence as a source of SARS‐CoV‐2 quasispecies
Li et al. Identification of the amino acid sequence in Sindbis virus nsP4 that binds to the promoter for the synthesis of the subgenomic RNA
Velasco et al. T-cell intracellular antigen 1-like protein in physiology and pathology
Zhang et al. AB‐type histone acetyltransferase Hat1 regulates secondary metabolism, conidiation, and cell wall integrity in the taxol‐producing fungus Pestalotiopsis microspora
CN109745311B (zh) RNase L酶抑制剂的应用
Kimura et al. Development of chemical tools to monitor and control isoaspartyl peptide methyltransferase activity
Li et al. NSvc4 encoded by rice stripe virus targets host chloroplasts to suppress chloroplast-mediated defense
Banerjee RNase L and the NLRP3-inflammasome: An old merchant in a new trade
CN115785200A (zh) 一组具有抗病毒活性的肽类化合物奥米克欣b族化合物的应用
Tang et al. A transcriptomic analysis of malignant transformation of human embryonic esophageal epithelial cells by HPV18 E6E7
Yahya et al. Profiling the physiological pitfalls of anti‐hepatitis C direct‐acting agents in budding yeast

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination